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A b s t r a c t
Diffuse midline gliomas, H3 K27M-mutant, World Health Organization (WHO) grade IV represent a distinct glioma 
entity with a predominantly paediatric presentation and remarkably poor prognosis. This report presents a case of 
a 73-year-old woman with a diffuse midline glioma, H3 K27M-mutant, WHO grade IV with a remarkable longitudinal 
extension, extending from the cervical myelon to the basal ganglia. On imaging, the lesion was predominantly sug-
gestive of inflammatory oedema, and it was clinically associated with progressive hemi- and later tetraparesis with 
severe autonomic and bulbar symptoms. Laboratory examinations suggested a generalized inflammatory process; 
however, neither infectious nor autoimmune aetiology could be confirmed. Biopsy was deemed unfeasible given the 
critical localization. Presuming a seronegative autoimmune encephalomyelitis, high-dose corticosteroid therapy and 
plasma exchanges were conducted, resulting in a modest but transient relief. The patient passed away two months 
after hospitalization. Neuropathological examination of the lesion revealed a high-grade diffuse glioma with H3 
K27M mutation (grade IV). Although originally considered as a paediatric entity, our case confirms reports from 
recent years that diffuse midline gliomas, H3 K27M-mutant, WHO grade IV can occur in adults, even among the 
elderly, and can mimic inflammatory alterations, posing diagnostic difficulty. Our case is one of the oldest patients 
reported with this pathology, the oldest with an extensive diffusely infiltrating growth pattern, and with the most 
extensive lesion reported in adulthood.
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Introduction
Diffuse midline glioma, H3 K27M-mutant, World 
Health Organization (WHO) grade IV represents a dis-
tinct entity of diffuse gliomas with a predominantly 
paediatric presentation and remarkably poor prog-
nosis [11,21]. Recurrent somatic K27M point mutation 
(i.e., lysine to methionine substitution at codon 27) 
in these tumours can affect either the H3F3A or the 
HIST1H3B genes, encoding histone H3 variants H3.3 
and H3.1, respectively, in a mutually exclusive fashion, 
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with the H3.3 K27M mutation being more common 
[21]. In addition, recurrent H3.3 mutations at codon 
34 with glycine to arginine or valine substitutions 
(G34R/V) have also been identified in paediatric as 
well as adult diffuse gliomas; however, H3.3 G34R/V-
mutant tumours are most predominantly hemispheric 
in location, are less frequent, and are associated with 
somewhat better prognosis, compared to patients 
with a tumour harbouring a K27M mutation [20,21].
Although diffuse midline glioma, H3 K27M-mu-
tant, WHO grade IV has been historically regarded as 
a strictly paediatric condition [21], case reports, case 
series, and larger studies have recently been pub-
lished with adult and rarely with elderly cases (Table I) 
[12,15]. Here we report one of the oldest patients 
having so far been reported with an immunohisto-
chemically confirmed diffuse midline glioma, H3 
K27M-mutant (WHO grade IV), with an exceptionally 
extensive longitudinal spread (extending from the 
cervical myelon to the basal ganglia) and non-spe-
cific imaging characteristics clinically mimicking an 
inflammatory process. The report was prepared in 
accordance with the CARE (CAse REport) guidelines 
[10]. All procedures performed were in accordance 
with the ethical standards of the 1964 Helsinki dec-
laration and its later amendments. The publication 
of the case report was approved by the Regional 
Human Biomedical Research Ethics Committee of 
the University of Szeged under registration number 
44/2016. The next-of-kin provided written informed 
consent for the publication of the case.
Case presentation
Clinical summary
A 73-year-old woman of Caucasian ethnicity was 
admitted to our neurology department from a rural 
hospital with 1-month history of progressive neuro-
logical signs and symptoms. Her complaints start-
ed with tingling of the right side of her mouth and 
tongue, and urinary incontinence. Two weeks later, 
she developed weakness of the facial muscles and 
extremities on the left side, followed by swallowing 
disturbance and faecal incontinence shortly before 
referral to our ward. Her past medical history was 
relevant for hypertension, a  thyroid nodule, and 
chronic cholecystitis. The family history included 
breast cancer in her mother.
On physical examination on admission, the 
patient presented with left-sided central facial pal-
sy, severe dysarthria, severe dysphagia, absent gag 
reflex, moderate left-sided hemiparesis with bilat-
eral pyramidal signs both on the upper and lower 
limbs (positive Hoffmann’s sign, Trömner’s sign, 
inverted radial reflex, and Babinski reflex), a  slight 
cerebellar ataxia in the right limbs, and a right-sided 
facial paraesthesia. The deep tendon reflexes were 
brisk in the upper but lost in the lower extremities. 
The patient was unable to sit and walk.
The multiple cranial nerve symptoms with the 
bilateral corticospinal tract involvement were sug-
gestive of a central nervous system (CNS) lesion 
involving the pontomedullary brainstem. A cranial 
computed tomography (CT) had already been per-
formed in the other institution with no abnormality 
detected. The magnetic resonance imaging (MRI) 
of the head and the neck performed in our hospital 
revealed a longitudinally extending confluent T2- and 
fluid-attenuated inversion recovery (FLAIR)-hyper-
intense lesion, starting from the second segment 
of the cervical spinal cord, extending through the 
medulla, the pons, the cerebral peduncles, and the 
internal capsules bilaterally, and extending to the 
right pallidum (Fig. 1). The lesion demonstrated no 
apparent Gadolinium contrast enhancement. On MR 
angiography, the large arteries were intact, and the 
diffusion-weighted image (DWI) was not indicative of 
ischaemic alteration (not shown). The presentation 
of the lesion was suggestive of interstitial oedema, 
raising the suspicion of an inflammatory alteration 
(i.e., brainstem encephalitis (including Bickerstaff 
brainstem encephalitis (BBE)), neuromyelitis opti-
ca spectrum disorder (NMOSD), or CNS vasculitis 
(including Behçet’s disease)) or an infiltrative tumour.
Laboratory examinations from the blood demon-
strated elevated inflammatory parameters sugges-
tive of systemic inflammation (i.e., elevated C-re-
active protein (CRP) level and sedimentation rate, 
slightly elevated levels of complements 3 and 4, and 
oligoclonal banding of gamma globulins, accompa-
nied by normal white blood cell count) and uniformly 
elevated liver enzymes. Small-vessel vasculitis with 
involvement of the cerebral vessels was addressed, 
but the serum was negative for typical autoantibod-
ies (including anti-neutrophil cytoplasmic antibodies 
(ANCA), anti-myeloperoxidase (MPO) and anti-pro-
teinase 3 (PR3) antibodies, as well as autoantibod-
ies of connective-tissue diseases). The elevated acti-
vated partial thromboplastin time (aPTT) and the 
results of the mixing test suggested the presence of 
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Fig. 1. Representative magnetic resonance imaging (MRI) scans of the elderly female patient with longitudi-
nally extending diffuse midline glioma mimicking encephalomyelitis. A) Axial cranial MRI fluid-attenuated 
inversion recovery (FLAIR) images with hyperintense lesion affecting the right-sided globus pallidus (with 
a suspicious vague hyperintensity in the overlying white matter as well), the internal capsules, the cerebral 
peduncles, the pontine basis and the cerebellar peduncles with right-sided predominance, and the medulla 
oblongata with a left-sided predominance. B) Sagittal cervical MRI T2 fast recovery fast spin-echo (FRFSE) 
images and C) corresponding short tau inversion recovery (STIR) images of the cervical spine demonstrating 
a longitudinally extensive hyperintense lesion suggestive of interstitial oedema. D) The lesion demonstrates 
a  longitudinally extending spread toward the upper cervical segments in forms of two distinct columns 
predominantly in the aspect of the anterior and lateral funiculi in axial T2 FRFSE images. E) No apparent 
Gadolinium contrast enhancement can be seen within the lesion (sagittal cervical T1 fast spin-echo (FSE) MRI 
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lupus anticoagulant; however, this alteration could 
as well have arisen secondary to the prophylacti-
cally administered low-molecular weight heparin 
(LMWH) therapy, limiting its interpretation [16]. No 
other anti-phospholipid antibodies were positive 
(including screening for anti-cardiolipin and anti-β-2- 
glycoprotein 1 antibodies). The routine cerebrospi-
nal fluid (CSF) investigation did not disclose any 
alteration (with a normal cell count and protein lev-
el), no signs of intrathecal immunoglobulin G (IgG) 
or immunoglobulin M (IgM) synthesis was detected 
by nephelometry, and oligoclonal bands were not 
present in the CSF (contrasting with the serum). No 
infectious agents were detected in the CSF (neither 
bacteria or fungus in the cultures nor neurotropic 
viruses (including herpes simplex virus (HSV) 1 and 2, 
Epstein-Barr virus (EBV), cytomegalovirus (CMV), 
enterovirus, and parechovirus) or Toxoplasma gon-
dii by real-time polymerase chain reaction (RT-PCR)), 
and no signs of active infection with neurotrop-
ic viruses (including HSV 1 and 2, varicella zoster 
virus, EBV, CMV, hepatitis B and C virus, human 
immunodeficiency virus 1 and 2, West-Nile virus, 
and tick-borne encephalitis virus) or Treponema 
pallidum could be detected by blood serology. Like-
wise, autoimmune encephalitis-associated antibod-
ies, onconeural auto- antibodies, anti-glutamic acid 
decarboxylase (GAD) antibody, anti-aquaporin-4 
(AQP4) antibody, and anti-myelin oligodendrocyte 
glycoprotein (MOG) antibody were not detected 
in the CSF (neither from the serum in the case of 
the last two). Based on the presence of corticospi-
nal signs and limb ataxia, the Guillain-Barré syn-
drome (GBS)-variant BBE also turned up as a pos-
sible diagnosis (even though ophthalmoplegia was 
not seen); therefore, anti-ganglioside GQ1b protein 
was tested, which was again negative. The patient 
was referred to the neurosurgery to facilitate histo-
logical diagnosis, but biopsy was not taken as the 
procedure was deemed overly hazardous due to the 
critical localization of the lesion. With the presump-
tive diagnosis of an inflammatory process in the 
CNS (with some of the above laboratory test results 
still pending), the administration of high-dose intra-
venous methyl-prednisolone (a total of 2.5 g) with 
empirical antibiotics (for the concomitant infec-
tions) was conducted, which resulted in a transient 
improvement in the patient’s state.
On follow-up cranial MRI scans (2 and 7 weeks 
after the initial one), no change in the extent of the 
lesion could be detected intracranially, with only 
the 7-week follow-up cervical MRI demonstrating 
a  slight progression to the caudal direction (not 
shown). Neuroradiological consultations consistent-
ly considered the lesion as inflammatory. The MRI 
spectroscopy suggested increased metabolism with-
in the lesion, with no further specification.
Over time, the hemiparesis became more se-
vere and later spread to the other side as well, 
and an almost complete anarthria and eventual-
ly a  decreased level of consciousness developed. 
Another cycle of pulse corticosteroid therapy was 
given (2.5 g), without any therapeutic success at this 
trial. As an ultimum refugium, the patient ex juvanti-
bus received plasma exchange four times, but it also 
had no positive result. Eventually, after 2 months 
of hospitalization and some 3 months of symptom 
onset, the patient passed away as a  consequence 
of recurrent nosocomial infections superimposed on 
the severe bed-ridden state.
Neuropathological assessment
Material and methods
The brain was fixed in buffered formalin for 
4 weeks. After fixation, coronal sections were per-
formed at 0.7-mm interval and several samples were 
taken from macroscopically identified alterations as 
well as from unremarkable distant areas. Haema-
toxylin-eosin-stained slides and immunostainings 
were performed according to standard protocols on 
4-µm formalin-fixed paraffin-embedded sections. 
The following antibodies were used: anti-glial fibril-
lary acidic protein (GFAP, mouse monoclonal, clone 
ASTRO6, 1 : 5000, Thermo Fisher Scientific, Waltham, 
MA, USA), anti-histone H3 (mutated K27M, rabbit 
monoclonal, clone EPR18340, 1 : 100, Abcam, Cam-
bridge, UK), anti-isocitrate dehydrogenase 1 (IDH1) 
(R132H mutant, mouse monoclonal, clone IHC132, 
1 : 200, GenomMe, Richmond, BC, Canada), anti-
Ki-67 (rabbit monoclonal, clone SP6, 1 : 100, Hiszto-
patológia Ltd., Pécs, Hungary), and anti-p53 (mouse 
monoclonal, clone DO7, 1 : 300, Sigma-Aldrich, St. 
Louis, MO, USA). The DAKO EnVision detection kit, 
peroxidase/3,3’-diaminobenzidine (DAB), rabbit/
mouse (Dako, Glostrup, Denmark) was used for 
visualization of antibody reactions. Photographs 
were taken using the CaseViewer software of a Pan-
noramic MIDI digital slide scanner (3D Histech, 
Budapest, Hungary).
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Fig. 2. A) Gross neuropathological examination of coronal brain slices reveals a diffusely infiltrating tumour 
predominantly involving the right cerebral peduncle, the basis of the pons, and the medulla oblongata. 
B) Haematoxylin-eosin staining of the cerebral peduncle demonstrates a hypercellular glial tumour with 
a  predominant fibrillary background, composed of highly pleomorphic cells with indistinct cell borders, 
variable amount of eosinophilic cytoplasm, and oval to irregular hyperchromatic nuclei. Mitotic figures are 
frequent and occasional bizarre multinucleated cells are also present (inset). C) The tumour shows diffuse 
immunopositivity for glial fibrillary acidic protein (GFAP), and D) a strong nuclear labelling for K27M-mutant 






On gross neuropathological examination, the 
cerebral hemispheres were symmetrical with no evi-
dence of focal lesion on the convex lateral surface. 
At the base of the brain, the pons and the medulla 
oblongata were mildly enlarged with slight asymme-
try. There was no evidence of uncal or tonsillar her-
niation. The basal arteries and cranial nerves were 
unremarkable. Coronal sections of the brainstem 
showed white, slightly blurred areas which were firm 
to touch, suggesting a diffusely infiltrating tumour, 
predominantly involving the cerebral peduncles (less 
apparently on the left side), the basis of the pons, 
and the right internal capsule (Fig. 2A). The infiltrat-
ed areas were slightly enlarged with mild distortion 
of the anatomical structures.
Histological work-up revealed a focally hypercel-
lular glial tumour diffusely infiltrating the cerebral 
peduncles, the basis of the pons, the right cerebel-
lar peduncle, and the medulla oblongata. Infiltrating 
tumour cells were also suspected along the white 
matter tract of the internal capsules. The tumour 
consisted of pleomorphic astrocytic cells with signifi-
cant mitotic activity and some bizarre multinucleated 
giant cells (Fig. 2B). There was only very mild micro-
vascular proliferation noted with no characteristic 
glomeruloid blood vessels. The infiltrated neurons 
were remarkably intact and no necrosis was identi-
fied in the tumour. Immunohistochemistry showed 
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strong diffuse positivity for GFAP in the tumour 
(Fig. 2C). The IDH1 (R132H) mutant clone was nega-
tive, most in keeping with an IDH-wildtype glioma at 
the age of the patient. No p53 overexpression was 
seen. The estimated proliferation index by Ki67 was 
about 8-9%. In addition, most of the tumour cells 
showed strong nuclear labelling for K27M-mutant 
histone H3 (H3 K27M), which confirmed the diag-
nosis of a diffuse midline glioma, H3 K27M-mutant, 
WHO grade IV (Fig. 2D).
Discussion
This case report demonstrates the diagnostic dif-
ficulty and the unexpected neuropathological diag-
nosis of a  rapidly progressing pathological lesion, 
which diffusely affected critical anatomical regions 
in the midline of the CNS, including the brainstem, 
in an elderly woman. The initial MRI images showed 
that the pathology was associated with interstitial 
oedema with an irregularly spreading confluent 
character, opening the question whether the oede-
ma was due to a  primary inflammation or a  neo-
plasm (including a high-grade glioma in a diffusely 
infiltrating pattern (i.e., without a  discrete tumour 
mass, reminiscent in this respect of the gliomatosis 
cerebri growth pattern, albeit not meeting its crite-
ria due to the lack of multilobar involvement) [9] or 
a primary CNS lymphoma in a lymphomatosis cere-
bri pattern [13] in the differential diagnosis). Due 
to the critical localization of the lesion, biopsy was 
not attempted by the neurosurgery. After initiating 
a  comprehensive evaluation for a  range of inflam-
matory conditions including autoimmune small-ves-
sel CNS vasculitides, CNS infections, paraneoplastic/
autoimmune encephalitides, NMOSD, and BBE, high-
dose corticosteroid therapy was administered with 
empirical and, subsequently, targeted antibiotics 
for systemic infections. The first cycle of pulse cor-
ticosteroid therapy moderately alleviated some of 
the symptoms, which supported the presumption 
of an immunological process; however, we did not 
manage to identify disease-specific autoantibodies 
either from the serum or from the CSF. This initial 
therapeutic response to the first trial of pulse cor-
ticosteroid therapy can be presumed to be due to 
a  decrease in tumour-associated oedema, retro-
spectively. On the basis of the serial negative results 
and the normal cell count and protein concentration 
in the CSF, a  potential seronegative CNS condition 
of immunological origin became a  less likely albeit 
the sole potentially treatable diagnosis (in fact the 
patient met the criteria of seronegative NMOSD). 
Though no investigation was performed that could 
have helped to differentiate between inflammato-
ry and neoplastic origin (with the MR spectroscopy 
revealing aspecific hypermetabolism indicative of 
both), the latter seemed more likely in an exclusion-
ary perspective, especially after the lack of symp-
tomatic relief after the second corticosteroid trial 
and the repeated plasma exchanges. An 18F-fluoro-
deoxyglucose (FDG) positron emission tomography 
(PET) CT and 11C-methionine (MET) PET-CT were also 
considered to address a  neoplastic origin; howev-
er, the broad literature on the limitations of these 
methods in differentiating inflammatory alterations 
from malignancies [4,17], the already very advanced 
clinical state of the patient at this stage, together 
with the inability to obtain in vivo histological diag-
nosis and thus to administer targeted therapy in 
case of a potential supportive finding overall result-
ed in a decision to omit this examination.
The definite diagnosis was built up by post mor-
tem histopathology and immunohistochemistry, 
revealing a  high-grade glioma. Given the midline 
localization of the tumour, examination for the his-
tone gene mutation H3 K27M was conducted immu-
nohistochemically, which yielded positive results, 
allowing the establishment of the diagnosis of dif-
fuse midline glioma, H3 K27M-mutant, WHO grade IV. 
This method is sensitive for both H3.3 and H3.1 
K27M mutations and has been documented to 
demonstrate 100% correspondence with the find-
ings of DNA sequencing [2,6]. Based on the fact that 
only post mortem, formalin-fixed, paraffin-embed-
ded tissue was available (yielding a high possibility 
of diagnostic failure for molecular analysis) and that 
the definite diagnosis of this glioma entity can be 
established on immunohistochemical grounds alone 
(reflected also by its exclusive use in a  number of 
recent larger-scale studies [5,12,18,19]), further spec-
ification of the locus of the H3 K27M mutation by 
molecular techniques was not performed.
This type of diffuse midline gliomas was clas-
sified as a  new entity in the 2016 WHO classifica-
tion of brain tumours as diffuse midline glioma, H3 
K27M-mutant, WHO grade IV [14]. Diffuse midline 
gliomas had originally been described in children 
and were historically referred to as paediatric diffuse 
intrinsic pontine gliomas (DIPGs). Molecular analysis 
revealed that some 70-80% of DIPGs carry H3 K27M 
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mutation, and are typically IDH-wildtype [11,21]. 
Tumours harbouring this mutation have remarkably 
poor prognosis despite treatment with adequate 
chemotherapy (temozolomide) and radiotherapy 
[11,15]; though this association in adult cases has 
recently been questioned [7,18]. The poorer progno-
sis compared to H3 wildtype gliomas may be related 
to the specific point mutation resulting in glioma-
genesis through epigenetic changes. Although orig-
inally described as a paediatric entity, more recent-
ly, diffuse midline gliomas, H3 K27M-mutant, WHO 
grade IV have been reported in young and even in 
elderly adults, with case reports and series appear-
ing in the literature only in the past few years [1,5-8, 
2,15,18,22] (Table I). To our knowledge, only two cas-
es have so far been reported that were older than 
our patient, an 82-year-old female patient with an 
isolated thalamic presentation and a 5.5-month sur-
vival [15], and an 81-year-old female patient with an 
isolated hypothalamic presentation and a 1.9-month 
survival [12]. As for the same 73 years of age, 2 male 
patients have so far been reported, with an isolated 
spinal cord involvement, however [6].
A  longitudinally extensive spread of paediatric 
diffuse midline gliomas has been well documented, 
including tumours harbouring an H3 K27M mutation, 
with some of the reported autopsy cases present-
ing with a lesion extending from the medulla to the 
frontal lobe [3]. Although a longitudinally extensive 
diffusely infiltrating growth pattern of such tumours 
in adults has also recently been documented [6,22], 
such an extensive diffuse midline glioma, H3 
K27M-mutant, WHO grade IV (extending from the 
cervical myelon to the basal ganglia) in adulthood, 
to our knowledge, is unique.
Conclusions
Though originally described as a paediatric enti-
ty, diffuse midline glioma, H3 K27M-mutant, WHO 
grade IV can occur in adults, even in the elderly. The 
longitudinally extensive topography and occasion-
ally non-specific imaging characteristics (as in our 
case) can mimic inflammatory CNS processes and 
represent a  diagnostic challenge, especially when 
biopsy is deemed unfeasible due to critical localiza-
tion of the lesion.
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